5,653 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 5,653 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the fourth quarter worth approximately $1,030,000. Harvey Capital Management Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $5,918,000. Hsbc Holdings PLC lifted its holdings in Halozyme Therapeutics by 35.0% during the third quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock worth $3,006,000 after buying an additional 20,346 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Halozyme Therapeutics by 174.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after buying an additional 563,989 shares during the period. Finally, Aurora Investment Counsel purchased a new stake in Halozyme Therapeutics during the third quarter worth $1,347,000. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. The Goldman Sachs Group lowered their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. Benchmark reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. Finally, TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.14.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $42.01 on Thursday. The firm has a market cap of $5.34 billion, a PE ratio of 19.91, a P/E/G ratio of 0.47 and a beta of 1.26. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a fifty day moving average price of $40.09 and a 200-day moving average price of $38.01. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock worth $1,196,800 in the last 90 days. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.